ADDIS ABABA, March 18 (Reuters) - The African Union said on
Thursday that it considers that the benefits of AstraZeneca's
COVID-19 vaccine outweigh the risks and recommended
that vaccinations continue across the continent.
The announcement came a day after the World Health
Organization backed the vaccine and as more than a dozen
European countries have suspended the use of it amid concerns
over the risk of blood clots.
John Nkengasong, director of the Africa Centers for Disease
Control and Prevention, told a news conference that the
"benefits still outweigh the risks" and that countries should
"move forward" with the vaccination.
AstraZeneca said on Sunday a review of safety data of more
than 17 million people vaccinated in the United Kingdom and
European Union with its vaccine had shown no evidence of an
increased risk of blood clots.
The head of the continent's disease control body said that
adverse reactions would be monitored and reported for future
assessments on the vaccine.
Some African countries have already suspended use of the
AstraZeneca vaccine.
On Friday the Democratic Republic of Congo delayed the
rollout of the shot, citing the suspension of the use of the
shots by European countries.
Many African states expect to receive AstraZeneca shots from
the COVAX Facility, a global vaccine allocation plan co-led by
the World Health Organization and partners including the Gavi
vaccines alliance, which will be delivering vaccines for free to
some low and lower-middle-income countries.
The European Medicines Agency is investigating reports of 30
cases of unusual blood disorders out of 5 million people who got
the AstraZeneca vaccine in the EU. It said it has so far found
no causal link.
(Reporting by Giulia Paravicini; Editing by Nick Macfie)
Astrazeneca (AZN)
